Understanding the BA.3.2 Variant: The Emergence of 'Cicada' and Its Impact on Vaccine Effectiveness
A new variant of COVID-19, known as BA.3.2 or "Cicada," has emerged, causing concern among health experts due to its mutations that may impact vaccine effectiveness. This variant is a descendant of the BA 3 variant, which has been dormant for several years. BA.3.2 has shown significant mutations compared to other variants and is part of the omicron family, potentially making it more contagious.
First detected in South Africa in November 2024, BA.3.2 has since been identified in the U.S., with a prevalence of 0.55%. While not yet the dominant strain in the U.S., it accounts for 30% of cases in European countries. The variant has been found in various states through wastewater and testing, with symptoms similar to other COVID variants, including fever, cough, and loss of taste or smell.
Despite concerns about its ability to evade vaccines, experts believe that current vaccines can still provide protection against severe illness caused by the Cicada variant. Alongside vaccination, practicing good hygiene measures like handwashing, mask-wearing, and social distancing remain crucial in preventing the spread of COVID-19.